Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naeem Ahmed

Internal Medicine Bay City, MI Medical Doctor

NPI 1720052020 CMS profile 123492

3720 Katalin Ct, Bay City, MI 48706

Open in the dashboard

General payments

$5,587

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naeem Ahmed of Bay City, MI is reported in the CMS Open Payments database as having received $5,587 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $656 33
2024 General $637 31
2023 General $838 42
2022 General $1,022 59
2021 General $1,286 81
2020 General $501 31
2019 General $646 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naeem Ahmed
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Naeem Ahmed were reported at $656. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Naeem Ahmed Internal Medicine median Middle half National median
2019 $646 $159 $48–$570 $163
2020 $501 $119 $33–$402 $114
2021 $1,286 $135 $37–$521 $132
2022 $1,022 $141 $42–$496 $149
2023 $838 $149 $45–$519 $160
2024 $637 $154 $47–$537 $164
2025 $656 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $407 20 payments
  2. Amgen Inc. $322 18 payments
  3. Novartis Pharmaceuticals Corporation $311 16 payments
  4. Pfizer Inc. $305 26 payments
  5. Merck Sharp & Dohme Corporation $282 17 payments
  6. Novo Nordisk Inc $257 15 payments
  7. AbbVie, Inc. $245 11 payments
  8. Janssen Pharmaceuticals, Inc $235 15 payments
  9. Nestle HealthCare Nutrition Inc. $227 16 payments
  10. GlaxoSmithKline, LLC. $216 13 payments
  11. Other $2,779 158 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,587 325 payments
Products named General payments · program years 2019–2025
  1. ZENPEP $248 17 payments
  2. XARELTO $235 15 payments
  3. MYRBETRIQ $226 12 payments
  4. ENTRESTO $204 12 payments
  5. ELIQUIS $201 13 payments
  6. Veozah $181 8 payments
  7. EVENITY $178 10 payments
  8. GARDASIL 9 $175 10 payments
  9. Ozempic $165 9 payments
  10. UBRELVY $161 6 payments
  11. Other $5,181 314 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 228 drugs

Part D claims

18,525

Median for Internal Medicine: 777

Drug cost

$1,466,254

Median for Internal Medicine: $73,373

Branded share of claims

23.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 663 $276,331
Trulicity Dulaglutide Brand 73 $89,362
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 74 $67,272
Xarelto Rivaroxaban Brand 91 $61,399
Ozempic Semaglutide Brand 40 $55,344
Mounjaro Tirzepatide Brand 37 $53,064
Januvia Sitagliptin Phosphate Brand 51 $50,301
Jardiance Empagliflozin Brand 107 $48,076
Xifaxan Rifaximin Brand 18 $38,011
Entresto Sacubitril/Valsartan Brand 77 $37,825

The 10 drugs with the highest cost, of 228 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$178,691

Of which drugs: $7,654

Medicare patients

514

Average age 76

Services billed

2,833

281 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 52%
Depression 50%
Diabetes 44%
Heart failure 42%
Atrial fibrillation 40%
COPD 38%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 50 50 $4,091
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 18 18 $2,354

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $37
  • Otsuka America Pharmaceutical, Inc. $25
$62 15 —
UBRELVY
  • AbbVie, Inc. $53
$53 — —
QULIPTA
  • AbbVie, Inc. $53
$53 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $47
$47 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $41
$41 663 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record